Company intelligence
abc biopply ag
Europe’s First Fully Integrated Organoid CRO
About abc biopply ag
Humanized Multi-Organoid Disease Models operated by Dedicated Organoid Competence Centers abc biopply AG provides validated highly predictive preclinical CRO services for drug efficacy, safety, toxicity, resistance, and biomarker development based on its proprietary 3D CoSeedis humanized multi-organoid technology™ on clinically relevant disease models (e.g. oncology, neurology, hepatic, obesity etc.) In addition, the technology allows us to custom tailor or design any disease model and than license it to our clients for in-house implementation and scale up. Highlights of our Integrated Organoid Services: - Preclinical assays: drug efficacy, safety, toxicology, IC50, dose response, relapse and resistance studies - Disease models: oncology, neurology, hepatic, renal, and cartilage - Custom-tailored model development and biomarker discovery - Integrated preclinical services, from in vitro to in vivo, synchronized with humanized mouse models via our partner Preclina Together, these offerings enable faster, more reliable drug discovery while reducing reliance on animal testing.
Verified activity
Signals from abc biopply ag
2 published signals
Products & Services
abc biopply ag is working towards making the step from conventional cell culture to more predictive human-relevant models a practical one.
Reported by Agne Vaitkeviciene
Products & Services
abc biopply ag developed the 3D CoSeedis™ technology platform for scalable, highly uniform and reproducible humanized Multi-Organoid NAM models.
Reported by abc biopply ag